Retrospective study of a novel anti-rheumatic drugs to reduce the panel reactive antibody of kidney transplant recipients
10.3760/cma.j.cn421203-20191023-00386
- VernacularTitle:新型抗风湿病药物降低肾移植受者群体反应性抗体水平的回顾性研究
- Author:
Hao CHEN
1
;
Min GU
;
Zhengkai HUANG
;
Dengyuan FENG
;
Li SUN
;
Zijie WANG
;
Shuang FEI
;
Jun TAO
;
Ruoyun TAN
;
Xiaobing JU
;
Zhijian HAN
Author Information
1. 南京医科大学第一附属医院泌尿外科 210029
- From:
Chinese Journal of Organ Transplantation
2020;41(3):163-168
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy and safety of Iguratimod in reducing the level of panel reactive antibodies in renal transplant recipients.Methods:The clinical data of 35 patients with PRA-positive renal transplant recipients were retrospectively analyzed. All recipients were treated with Iguratimod for PRA-positive. The changes in PRA levels before and after treatment and the adverse events were observed.Results:Of the 35 recipients, 4 of them were discontinued due to pulmonary infection, and 2 patients were discontinued during the observation period. 3 patients were lost to follow-up. A total of 26 recipients were included. When Iguratimod was taken to 9 months, the PRA was reviewed. 71.5 % of the 207 sites showed a downward trend, 69.9 % of the 107 class I sites and 75.9 % of the 41 class II site showed a downward trend, and there was no difference in renal function before and after treatment. There were no significant changes in blood routine, liver function, blood lipids, and blood glucose. There were no other adverse events.Conclusions:Iguratimod can effectively reduce the level of PRA in renal transplant recipients with less adverse events.
